Literature DB >> 8301571

Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine.

N L Benowitz1, P Jacob, I Fong, S Gupta.   

Abstract

The objectives of this study were to 1) quantitatively assess human exposure to various metabolites of nicotine, 2) examine the influence of inhalation vs. transdermal administration on the patterns of nicotine metabolism, and 3) assess the extent of recovery of nicotine as various metabolites in people whose systemic intake of nicotine has been measured. Twelve smokers were studied while smoking cigarettes and while receiving transdermal nicotine. Urinary excretion of nicotine and eight of its metabolites was measured under steady state conditions. The systemic intake of nicotine in these subjects was determined using plasma concentrations and intravenous clearance data, so the percentage of their daily dose of nicotine excreted as various metabolites could be computed. The major findings of the study are as follows: 1) a high percentage (averaging 88%) of a systemic dose of nicotine can be accounted for by measurement of nicotine and its metabolites; 2) the pattern of metabolism is generally similar when nicotine is inhaled or absorbed transdermally; 3) while there is considerable interindividual variability in the pattern of metabolism, the pattern is consistent for an individual; and 4) within individuals, the extent of conjugation of nicotine and cotinine is highly correlated, but neither is correlated with the extent of conjugation of 3'-hydroxycotinine. This suggests that similar enzymes are involved in the conjugation of nicotine and cotinine, and that a different enzyme may be involved in the conjugation of 3'-hydroxycotinine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8301571

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  87 in total

1.  Cigarette nicotine yields and nicotine intake among Japanese male workers.

Authors:  K Ueda; I Kawachi; M Nakamura; H Nogami; N Shirokawa; S Masui; A Okayama; A Oshima
Journal:  Tob Control       Date:  2002-03       Impact factor: 7.552

2.  Environmental and genetic determinants of tobacco use: methodology for a multidisciplinary, longitudinal family-based investigation.

Authors:  Gary E Swan; Karen Suchanek Hudmon; Lisa M Jack; Kymberli Hemberger; Dorit Carmelli; Taline V Khroyan; Huijun Z Ring; Hyman Hops; Judy A Andrews; Elizabeth Tildesley; Dale McBride; Neal Benowitz; Chris Webster; Kirk C Wilhelmsen; Heidi S Feiler; Barbara Koenig; Lorraine Caron; Judy Illes; Li S-C Cheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-10       Impact factor: 4.254

3.  Estimation of nicotine dose after low-level exposure using plasma and urine nicotine metabolites.

Authors:  Neal L Benowitz; Katherine M Dains; Delia Dempsey; Lisa Yu; Peyton Jacob
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05       Impact factor: 4.254

4.  UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.

Authors:  Jeannette Zinggeler Berg; Linda B von Weymarn; Elizabeth A Thompson; Katherine M Wickham; Natalie A Weisensel; Dorothy K Hatsukami; Sharon E Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

5.  Bupropion for smoking cessation in African American light smokers: a randomized controlled trial.

Authors:  Lisa Sanderson Cox; Nicole L Nollen; Matthew S Mayo; Won S Choi; Babalola Faseru; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia
Journal:  J Natl Cancer Inst       Date:  2012-01-25       Impact factor: 13.506

6.  Population pharmacokinetics of nicotine and its metabolites I. Model development.

Authors:  Micha Levi; Delia A Dempsey; Neal L Benowitz; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-06       Impact factor: 2.745

7.  Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples II. Model application.

Authors:  Micha Levi; Delia A Dempsey; Neal L Benowitz; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-06       Impact factor: 2.745

8.  Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.

Authors:  Gang Chen; Nino E Giambrone; Douglas F Dluzen; Joshua E Muscat; Arthur Berg; Carla J Gallagher; Philip Lazarus
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

Review 9.  Nicotinic receptors containing the alpha7 subunit: a model for rational drug design.

Authors:  G Sharma; S Vijayaraghavan
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

10.  Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms.

Authors:  A Joseph Bloom; Timothy B Baker; Li-Shiun Chen; Naomi Breslau; Dorothy Hatsukami; Laura J Bierut; Alison Goate
Journal:  Hum Mol Genet       Date:  2013-09-17       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.